Literature DB >> 32170734

A novel mouse model of glucagon-like peptide-1 receptor expression: A look at the brain.

Devon L Graham1, Heather H Durai2, Taylor S Trammell1, Brenda L Noble1, Douglas P Mortlock3, Aurelio Galli4, Gregg D Stanwood1.   

Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone with a number of functions to maintain energy homeostasis and contribute to motivated behavior, both peripherally and within the central nervous system (CNS). These functions, which include insulin secretion, gastric emptying, satiety, and the hedonic aspects of food and drug intake, are primarily mediated through stimulation of the GLP-1 receptor. While this receptor plays an important role in a variety of physiological outcomes, data regarding its CNS expression has been primarily limited to regional receptor binding and single-label transcript expression studies. We thus developed a bacterial artificial chromosome transgenic mouse, in which expression of a red fluorescent protein (mApple) is driven by the GLP-1R promoter. Using this reporter mouse, we characterized the regional and cellular expression patterns of GLP-1R expressing cells in the CNS, using double-label immunohistochemistry and in situ hybridization. GLP-1R-expressing cells were enriched in several key brain regions and circuits, including the lateral septum, hypothalamus, amygdala, bed nucleus of the stria terminalis, hippocampus, ventral midbrain, periaqueductal gray, and cerebral cortex. In most regions, GLP-1R primarily colocalized with GABAergic neurons, except within some regions such as the hippocampus, where it was co-expressed in glutamatergic neurons. GLP-1R-mApple cells were highly co-expressed with 5-HT3 receptor-containing neurons within the cortex and striatum, as well as with dopamine receptor- and calbindin-expressing cells within the lateral septum, the brain region in which GLP-1R is most highly expressed. In this manuscript, we provide detailed images of GLP-1R-mApple expression and distribution within the brain and characterization of these neurons.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  GLP-1; GLP-1R; RRID:AB_10000320; RRID:AB_10000347; RRID:AB_10013483; RRID:AB_10617228; RRID:AB_11211549; RRID:AB_11212597; RRID:AB_2079751; RRID:AB_2088494; RRID:AB_2255365; RRID:AB_2278725; RRID:AB_2298772; RRID:AB_2534023; RRID:AB_2811192; RRID:AB_477329; RRID:AB_477560; hypothalamus; incretin; lateral septum; striatum; transgenic

Mesh:

Substances:

Year:  2020        PMID: 32170734      PMCID: PMC7392814          DOI: 10.1002/cne.24905

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  96 in total

1.  Dbx1 triggers crucial molecular programs required for midline crossing by midbrain commissural axons.

Authors:  Yasuyuki Inamata; Ryuichi Shirasaki
Journal:  Development       Date:  2014-02-19       Impact factor: 6.868

2.  LN-6: a monoclonal antibody to vimentin expressed in non-hematopoietic mesenchymal cells and derived tumors and reactive in B5-fixed, paraffin-embedded tissues.

Authors:  E Stathopoulos; G S Naeve; C R Taylor; A L Epstein
Journal:  J Histochem Cytochem       Date:  1989-09       Impact factor: 2.479

3.  The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon.

Authors:  M Morales; F E Bloom
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

4.  Glucagon-like peptide-1 7-36: a physiological incretin in man.

Authors:  B Kreymann; G Williams; M A Ghatei; S R Bloom
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

5.  GLP-1 analog attenuates cocaine reward.

Authors:  D L Graham; K Erreger; A Galli; G D Stanwood
Journal:  Mol Psychiatry       Date:  2012-10-23       Impact factor: 15.992

6.  Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor.

Authors:  B Eisensamer; G Rammes; G Gimpl; M Shapa; U Ferrari; G Hapfelmeier; B Bondy; C Parsons; K Gilling; W Zieglgänsberger; F Holsboer; R Rupprecht
Journal:  Mol Psychiatry       Date:  2003-11       Impact factor: 15.992

7.  The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.

Authors:  Emil Egecioglu; Jörgen A Engel; Elisabet Jerlhag
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

8.  Neural Correlates of Fear in the Periaqueductal Gray.

Authors:  Thomas C Watson; Nadia L Cerminara; Bridget M Lumb; Richard Apps
Journal:  J Neurosci       Date:  2016-11-09       Impact factor: 6.167

9.  NeuN, a neuronal specific nuclear protein in vertebrates.

Authors:  R J Mullen; C R Buck; A M Smith
Journal:  Development       Date:  1992-09       Impact factor: 6.868

10.  Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.

Authors:  Simon C Cork; James E Richards; Marie K Holt; Fiona M Gribble; Frank Reimann; Stefan Trapp
Journal:  Mol Metab       Date:  2015-08-05       Impact factor: 7.422

View more
  18 in total

Review 1.  A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors.

Authors:  Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neurosci Biobehav Rev       Date:  2021-10-29       Impact factor: 8.989

2.  Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in mice.

Authors:  Yvette Ruska; Anett Szilvásy-Szabó; Dóra Kővári; Andrea Kádár; Lilla Mácsai; Richárd Sinkó; Erik Hrabovszky; Balázs Gereben; Csaba Fekete
Journal:  Brain Struct Funct       Date:  2021-10-01       Impact factor: 3.270

Review 3.  The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.

Authors:  Niklas Reich; Christian Hölscher
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

4.  Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease.

Authors:  Vicki Wang; Tung-Tai Kuo; Eagle Yi-Kung Huang; Kuo-Hsing Ma; Yu-Ching Chou; Zhao-Yang Fu; Li-Wen Lai; Jin Jung; Hoi-Ii Choi; Doo-Sup Choi; Yazhou Li; Lars Olson; Nigel H Greig; Barry J Hoffer; Yuan-Hao Chen
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-16

Review 5.  Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.

Authors:  Christian Hölscher
Journal:  Br J Pharmacol       Date:  2021-05-29       Impact factor: 8.739

6.  A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.

Authors:  Yafang Zhang; Suditi Rahematpura; Kael H Ragnini; Amanda Moreno; Kamryn S Stecyk; Michelle W Kahng; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neuropharmacology       Date:  2021-05-11       Impact factor: 5.273

7.  Long-term functional alterations following prenatal GLP-1R activation.

Authors:  Devon L Graham; Haley S Madkour; Brenda L Noble; Chris Schatschneider; Gregg D Stanwood
Journal:  Neurotoxicol Teratol       Date:  2021-04-20       Impact factor: 4.071

8.  GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner.

Authors:  Taylor S Trammell; Natalie L Henderson; Haley S Madkour; Gregg D Stanwood; Devon L Graham
Journal:  Neurol Sci       Date:  2020-11-22       Impact factor: 3.830

9.  Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.

Authors:  Vincent N Marty; Mehdi Farokhnia; Joseph J Munier; Yatendra Mulpuri; Lorenzo Leggio; Igor Spigelman
Journal:  Front Neurosci       Date:  2020-12-23       Impact factor: 4.677

Review 10.  Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress.

Authors:  Yolanda Diz-Chaves; Salvador Herrera-Pérez; Lucas C González-Matías; José Antonio Lamas; Federico Mallo
Journal:  Nutrients       Date:  2020-10-28       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.